Edwards Lifesciences (Edwards Lifesciences) Change In Working Capital : $-526 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Edwards Lifesciences Change In Working Capital?

Edwards Lifesciences's change in working capital for the quarter that ended in Dec. 2023 was $-216 Mil.

Edwards Lifesciences's change in working capital for the fiscal year that ended in Dec. 2023 was $-526 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Edwards Lifesciences Change In Working Capital Historical Data

The historical data trend for Edwards Lifesciences's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Change In Working Capital Chart

Edwards Lifesciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-200.80

42.20

145.30

-421.40

-526.30

Edwards Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-84.90	-56.60	-241.40	-12.20	-216.10

Edwards Lifesciences Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-526 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Edwards Lifesciences Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Edwards Lifesciences (Edwards Lifesciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (NYSE:EW) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

EW:Mexico 1EW:Italy EWL:Germany EWL:Germany EWL:Germany E1WL34:Brazil EWLS:Austria

Address

One Edwards Way, Irvine, CA, USA, 92614

Website

https://www.edwards.com

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Executives

Bobo Donald E Jr	officer: CVP,Strategy/Corp Development	C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Michael A Mussallem	director, officer: Chairman & CEO	C/O EDWARDS LIFESCIENCES CORP, ONE EDWARDS WAY, IRVINE CA 92614
Scott B. Ullem	officer: CVP, CFO	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Daveen Chopra	officer: CVP, Surgical Structural Heart	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92618
Larry L Wood	officer: CVP, THV Replacement	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Catherine M. Szyman	officer: CVP, Critical Care	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Wayne Markowitz	officer: GM & SVP, Surgical	ONE EDWARDS WAY, IRVINE CA 92614
Heisz Leslie Stone	director	C/O PUBLIC STORAGE, 701 WESTERN AVENUE, GLENDALE CA 91201
Jean-luc M Lemercier	officer: CVP, EMEA, Canada, Latin Amer	C/O ONE EDWARDS WAY, IRVINE CA 92614
Sellers Robert W.a.	officer: VP, Corp. Controller (Principa	ONE EDWARDS WAY, IRVINE CA 92614
Bernard J Zovighian	officer: CVP, Surgical Heart Valves	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Huimin Wang	officer: CVP, Japan & Intercontinental	C/O EDWARDS LIFESCIENCES, ONE EDWARDS WAY, IRVINE CA 92614
Martha H. Marsh	director	9769 WEXFORD CIRCLE, GRANITE BAY CA 95746
Kieran Gallahue	director	PO BOX 684369, PARK CITY UT 84068
Nicholas J Valeriani	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614